scholarly journals Unresolved chronic ulcerated nodules: Disseminated Cutaneous Sporotrichosis

2022 ◽  
Vol 21 (1) ◽  
pp. 191-195
Author(s):  
Nurkhaniza Kaman ◽  
Azlina Ishak ◽  
Juliawati Muhammad
Keyword(s):  
Side Effects ◽  
Clinical Improvement ◽  
Male Patient ◽  
Correct Diagnosis ◽  
Medical Science ◽  
Good Compliance ◽  
Significant Clinical Improvement ◽  
Nodular Vasculitis

We present a case of disseminated cutaneous sporotrichosis in a 72-year-old male patient who has multiple ulcerated painless nodules over the left side of his chest and on his upper and lower left limbs for three years. He was initially diagnosed to have nodular vasculitis based on early repeated biopsies. Despite the patient’s good compliance with his prednisolone medication, no significant clinical improvement was observed. Another biopsy, which was arranged after two years of treatment for nodular vasculitis, supported the diagnosis of sporotrichosis. Itraconazole was initiated, and all the lesions showed a remarkable response toward the treatment. The delay in finding the correct diagnosis unnecessarily exposed the patient to the side effects of steroid and caused the disease to worsen. Bangladesh Journal of Medical Science Vol. 21(1) 2022 Page : 191-195

scholarly journals The effectiveness of Fractional CO2 laser and long-pulsed ND- YAG laser in managing striae

2021 ◽  
Author(s):  
Hendawy AF ◽  
Aly DG ◽  
Shokeir HA ◽  
Samy NA
Keyword(s):  
Side Effects ◽  
Clinical Improvement ◽  
Co2 Laser ◽  
Nd:Yag Laser ◽  
The Other ◽  
Yag Laser ◽  
Fractional Co2 Laser ◽  
Pregnant Females ◽  
Significant Difference ◽  
Significant Clinical Improvement

Abstract Background: Striae Distansae (SD) are a disfiguring dermal condition, characterized by linear bands of atrophic skin, occurring at sites of dermal damage caused by stretching. They affect adolescents and more than 70% of pregnant females due to stretching of the skin. Aims: To evaluate and to compare the efficacy of 1, 064 nm Long Pulsed Nd: YAG laser and Fractional CO2 laser in the management of SD. Patients/Methods: Thirty female patients with bilateral symmetrical SD were treated with Fractional CO2 laser on one side and long-pulsed Nd: YAG laser on the other side. All patients received 3 sessions at 3 weeks interval. Global Aesthetic improvement scale (GAIS) and was used to evaluate improvement 3 months post treatment. Four mm punch biopsies were taken from each side before treatment and 3 months after the last session to measure epidermal and collagen thickness. Findings: More significant clinical improvement was noted with the Nd:YAG laser than Fractional CO2 laser. Both GAIS and satisfaction score were significantly higher in the Nd:YAG laser treated side epidermal and collagen thickness were evidently increased in the Nd: YAG laser treated lesions than those treated by Fractional CO2 laser with no significant difference. Conclusions: Long pulsed Nd-YAG laser is clinically more effective than the Fractional CO2 laser in treating SD without serious side effects, although there was no significant difference between them histopathologically.

scholarly journals Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience

2020 ◽  
Vol 11 ◽  
Author(s):  
Aurélien Mary ◽  
Lucie Hénaut ◽  
Pierre Yves Macq ◽  
Louise Badoux ◽  
Arnaud Cappe ◽  
...  
Keyword(s):  
Side Effects ◽  
Clinical Improvement ◽  
The United States ◽  
University Hospital ◽  
Inhalation Therapy ◽  
Type I ◽  
Intensive Care Patients ◽  
Significant Clinical Improvement ◽  
Systemic Side Effects ◽  
Set Up

The inflammatory response to COVID-19 is specifically associated with an impaired type I interferon (IFN) response and complete blockade of IFN-β secretion. Clinically, nebulization of IFN-α-2b has been historically used in China to treat viral pneumonia associated with SARS-CoV. Very recent data show that the use of inhaled type I IFN is associated with decreased mortality in Chinese COVID-19 patients. However, IFN nebulization is currently not standard in Europe and the United States. Therefore, our group has set up a project aimed to evaluate the possibility to nebulize IFN-β-1b (a drug currently used in Europe to treat multiple sclerosis via subcutaneous injections) and to assess the safety of this new mode of administration in SARS-CoV-2 infected patients. We present here literature data that allowed us to build our hypothesis and to develop collaboration between clinical pharmacists, intensivists and nebulization engineers in order to gain first pre-clinical and clinical experience of IFN-β-1b nebulization. After validation of the nebulization method and verification of droplet size compatible with nebulization, the method has been applied to four intensive care patients treated at our university hospital, for whom none of the COVID-19 therapies initially used in France led to significant clinical improvement. All patients exhibited negative viral carriage and experienced clinical improvement 7–16 days after having initiated nebulized IFN-β-1b inhalation therapy. No side effects were observed. All patients were alive within a 90-days follow-up. Although it is not possible to draw firm conclusions on treatment efficacy based on this case report, our study shows that pulmonary IFN-β-1b administration is feasible, with a good safety profile. This procedure, which presents the advantage of directly targeting the lungs and reducing the risks of systemic side effects, may represent a promising therapeutic strategy for the care of patients with severe COVID-19. However, our preliminary observation requires confirmation by randomized controlled trials.

Clinical Study of Shirishadi tablet in the management of Tamaka Shvasa w.s.r. to Bronchial Asthma

2017 ◽  
Vol 2 (4) ◽  
Author(s):  
Pankaj Chhayani ◽  
Hemang Raghavani ◽  
Dhananjay Patel
Keyword(s):  
Internal Medicine ◽  
Clinical Study ◽  
Side Effects ◽  
Bronchial Asthma ◽  
Medical Science ◽  
Signs And Symptoms ◽  
Effective Remedy ◽  
All Diseases

Tamaka Shvasa is described as a most difficult to cure (Yapya) among all diseases in Ayurveda. In present study Tamaka Shvasa is correlated with Bronchial Asthma because of its symptomatology is much similar with Tamaka Shvasa. In modern medical science, steroids and bronchodilators are mainly used for its management, but they cause certain side effects. Present study was undertaken to provide safe and effective remedy for Tamaka Shvasa through Ayurvedic medicaments. Shirishadi tablet was given as internal medicine for 30 days. Upto 60% relief was found in signs and symptoms of Tamaka Shvasa.

scholarly journals Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis

Biomolecules ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. 136 ◽  
Author(s):  
Levent Kilic ◽  
Abdulsamet Erden ◽  
Yusuf Sener ◽  
Berkan Armagan ◽  
Alper Sari ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Improvement ◽  
Inflammatory Diseases ◽  
Case Series ◽  
New Drugs ◽  
Renal Amyloidosis ◽  
Secondary Amyloidosis ◽  
Aa Amyloidosis ◽  
Amyloid A ◽  
Significant Clinical Improvement

Secondary amyloid A (AA) amyloidosis is a late and serious complication of poorly controlled, chronic inflammatory diseases. Rheumatoid arthritis (RA) patients with poorly controlled, longstanding disease and those with extra-articular manifestations are under risk for the development of AA amyloidosis. Although new drugs have proven to be significantly effective in the treatment of secondary AA amyloidosis, no treatment modality has proven to be ideal. To date, only in small case series preliminary clinical improvement have been shown with rituximab therapy for AA amyloidosis secondary to RA that is refractory to TNF-α inhibitors (TNF-i) therapy. In these case series, we assessed the efficacy and safety of rituximab therapy for patients with RA and secondary amyloidosis. Hacettepe University Biologic Registry was developed at 2005. The data of the RA patients who were prescribed a biological drug were recorded regularly. Patients with biopsy proven AA amyloidosis patients were screened. Of 1022 RA patients under biologic therapy, 0.7% patients had clinically apparent histologically confirmed amyloidosis. Four of seven patients who were prescribed rituximab at least one infusion enrolled to those case series. Two of four patients showed significant clinical improvement and one of them also had decrease in proteinuria and the other one had stable renal function and proteinuria. The main goal for the treatment of AA amyloidosis is to control the activity of the underlying disorder. In this study, we showed that rituximab may be an effective treatment in RA patients with amyloidosis who were unresponsive to conventional disease modifying anti-rheumatic drugs (DMARDs) and/or TNFi.

scholarly journals Alternative Leprosy Treatment Using Rifampicin Ofloxacin Minocycline (ROM) Regimen – Two Case Reports

2019 ◽  
Vol 11 (3) ◽  
pp. 89-93
Author(s):  
Yohanes Widjaja ◽  
Khairuddin Djawad ◽  
Saffruddin Amin ◽  
Widyawati Djamaluddin ◽  
Dirmawati Kadir ◽  
...  
Keyword(s):  
Clinical Improvement ◽  
Alternative Treatment ◽  
Histopathological Examination ◽  
Case Reports ◽  
Erythematous Plaque ◽  
First Case ◽  
Satisfactory Outcome ◽  
Significant Clinical Improvement ◽  
The Right

Abstract Introduction. Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in neuropathy and associated long-term consequences, including deformities and disabilities. According to the WHO classification, there are two categories of leprosy, paucibacillary (PB) and multibacillary (MB). The standard treatment for leprosy employs the use of WHO MDT (Multi Drug Treatment) regimen, despite its multiple downsides such as clofazimine-induced pigmentation, dapsone-induced haematological adverse effects, poor compliance due to long therapy duration, drug resistance, and relapse. Multiple studies and case reports using ROM regimen have reported satisfactory results. Nevertheless, there are still insufficient data to elucidate the optimum dosage and duration of ROM regimen as an alternative treatment for leprosy. Previous experience from our institution revealed that ROM regimen given three times weekly resulted in a satisfactory outcome. Case Reports. We report two cases of leprosy treated with ROM regimen from our institution. The first case was PB leprosy in a 64-year-old male who presented with a single scaly plaque with erythematous edge on the right popliteal fossa. Sensibility examination showed hypoesthesia with no peripheral nerve enlargement. Histopathological examination confirmed Borderline Tuberculoid leprosy. ROM regimen was started three times weekly for 6 weeks and the patient showed significant clinical improvement at the end of the treatment with no reaction or relapse until after 6 months after treatment. The second case was MB leprosy in a 24-year-old male patient with clawed hand on the 3rd-5th phalanges of the right hand and a hypoesthetic erythematous plaque on the forehead. Histopathology examination confirmed Borderline leprosy. The patients received ROM therapy 3 times a week with significant clinical improvement after 12 weeks. Conclusion. ROM regimen given three times weekly for 6 weeks in PB leprosy and 12 weeks in MB leprosy resulted in a significant clinical improvement. Thus, ROM regimen could be a more effective, safer, faster alternative treatment for leprosy.

scholarly journals Non-Healing Ulcer, managed through Unani Formulation along with Leech Therapy: A Case Study

2019 ◽  
Vol 9 (6-s) ◽  
pp. 211-215
Author(s):  
Minhaj Ahmad ◽  
Zehra Zaidi ◽  
Abdul Nasir
Keyword(s):  
Side Effects ◽  
Male Patient ◽  
Severe Pain ◽  
New Delhi ◽  
Healing Ulcer ◽  
Unani Medicine ◽  
Leech Therapy ◽  
The Right ◽  
Local Examination

A male patient aged 43yrs. came to surgery OPD Majeedia Unani Hospital Jamia Hamdard New Delhi, in September 2018 with the complain of ulcer in the right foot posteriorly along the necrosis of Tendon Achilles. He was unable to walk a distance of about 100 meter due severe pain in the ulcer and calf muscle. limping on movement was very prominent. After required investigations and local examination of wounds, patient was planned and treated by local application, and combination of Unani Medicines formulations along with leech therapy as described in texts of Unani System of Medicine. With this Unani treatment non healing ulcer completely healed without any locomotor disturbances. The condition of leg totally resolved without any complications and side effects. Keywords: Non healing ulcer, Unani medicine, leech therapy.

scholarly journals Insight of COVID-19/ SARS-CoV-2 and its Probable Treatment - A Mathematical Approach

2020 ◽  
Author(s):  
Amar Nath Chatterjee ◽  
Shubhankar Saha ◽  
Priti Kumar Roy ◽  
Fahad Al Basir ◽  
Evgenii Khailov ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Complex Dynamics ◽  
Medical Science ◽  
Threshold Value ◽  
Drug Dosage ◽  
Equilibrium Analysis ◽  
Combination Drug ◽  
Drug Dosing ◽  
Novel Coronavirus

Abstract The novel coronavirus disease (COVID19) emerged in Wuhan, China in December 2019. In a matter of weeks, the disease had spread well outside China, and now reaching countries in all parts of the globe. Its treatment and recovery are the two most primary concerns for every country. Recently, medical science has shown some studies that reveal post-infection Hydroxychloroquine (HCQ) treatment followed by lipopeptide EK1C4 could be an effective interference in prevention of the disease COVID19, spreaded by SARS-CoV-2. However, there are some side effects of these drugs, especially for aged persons, but this is yet to be explored by rescaling the drug dosage with a proper dosing time interval.We propose a mathematical model that explains combination drug therapy on the dynamics of SARSCoV-2/COVID19. We apply the method of impulsive differential equation in our model and it is useful for elucidating insights into regular drug dosing. Systematic approach of this combination of drug therapy allows us to gain more fruitful results.In this model, we first investigate the chaotic nature of the system induced by SARS-CoV-2 with and without any treatment. Then we enquire how drug therapy reduces the threshold value of infection and observe its complex dynamics. We perform equilibrium analysis, local and global stability analysis and find the region of safe dosing so that there occurs no side-effects during treatment and afterwards. Our results suggest that only proper treatment enhances the stability in a SARS-CoV-2 infected system.

scholarly journals Pharmacogenomics- The Promise of Personalized Medicine

2013 ◽  
Vol 12 (4) ◽  
pp. 346-356 ◽  
Author(s):  
M Fakruddin ◽  
A Chowdhury
Keyword(s):  
Side Effects ◽  
Personalized Medicine ◽  
Development Process ◽  
Genetic Basis ◽  
Ethical Issues ◽  
Medical Science ◽  
Medical Community ◽  
Pharmaceutical Companies ◽  
Current Therapies ◽  
Genetic Makeup

Introduction: Pharmacogenomics (PGx) is the study of the genetic basis of variability among individuals in response to drugs. It is the newest discipline of medicine and is becoming a very active area of research, with the pharmaceutical industry gaining experience applying it, integrating it into the drug development process, and also learning to better manage the expectations of the medical community. Methodology: A comprehensive review of the literature on the principles, applications, challenges and prospects of pharmacogenomics was performed. Results: Pharmacogenomics tailors therapies to the genetic makeup of an individual and can therefore offer treatments that are more efficacious and have fewer side effects. Despite these benefits, personalized medicine has not been embraced by large pharmaceutical companies. It is expected that the first wave of successful pharmacogenomics products will be used in acute treatments for which current therapies have and severe side effects. These products should also be good candidates for premium pricing. Personalized medicine (PM), based on the genetic makeup of a patient, may result in not only an improved therapeutic response but also a clinically important reduction in adverse drug reactions. The experience to date is mixed, with a few successes but many frustrations. Conclusion: However, for pharmacogenomics to be truly embraced, the benefits of this technology must become more widely accepted in terms of economic, public, regulatory and ethical issues. DOI: http://dx.doi.org/10.3329/bjms.v12i4.11041 Bangladesh Journal of Medical Science Vol. 12 No. 04 October ’13 Page 346-356

Disulfiram-induced epileptic seizures

2021 ◽  
Vol 14 (3) ◽  
pp. e236296
Author(s):  
Violeta Nogueira ◽  
Mafalda Azevedo Mendes ◽  
Inês Pereira ◽  
Joana Teixeira
Keyword(s):  
Adverse Effect ◽  
Side Effects ◽  
Alcohol Consumption ◽  
Alcohol Dependence ◽  
Male Patient ◽  
Epileptic Seizure ◽  
Therapeutic Agent ◽  
Epileptic Seizures ◽  
Clinical Complications ◽  
Clonic Seizures

Disulfiram has been widely used for over six decades in the treatment of alcohol dependence, as an aversive therapeutic agent. Despite having very few side effects when taken without concurrent alcohol consumption, some of these may underlie serious clinical complications. Epileptic seizure induction is a rare adverse effect of disulfiram and its aetiological mechanism is unknown. We present a hospitalised 47-year-old male patient with two episodes of generalised tonic-clonic seizures during treatment with disulfiram while abstinent from alcohol.

Sign in / Sign up

Export Citation Format

Share Document